Peter J. Schnorr

TL;DR: Disruption of the interaction of CD47 with SIRPα using anti-CD47 antibodies induced macrophage-mediated phagocytosis of human SCLC patient cells in culture, and this approach could enable personalized immunotherapeutic regimens in patients with S CLC and other cancers.

TL;DR: It is shown that host HSC clearance is dependent on Fc-mediated antibody effector functions, and enhancing effector activity through blockade of CD47, a myeloid-specific immune checkpoint, extends anti–c-Kit conditioning to fully immunocompetent mice, which leads to elimination of >99% of host H SCs and robust multilineage blood reconstitution after HSC transplantation.

TL;DR: An understanding of hematopoiesis and myeloid cell development has implications for regenerative medicine, hematoietic cell transplantation, malignancy, and many other diseases.

TL;DR: This is the first in-depth profiling of pancreatic neuroendocrine tumors (PanNETs), to the authors' knowledge, that illuminates fundamental biological processes for this class of tumors and demonstrates that MET proto-oncogene activation is important for tumor growth in PanNET xenograft models.

TL;DR: It is found the canine CD47/SIRPα axis to be conserved biochemically and functionally and to support further testing of CD47-blocking therapies alone and in combination with CD20 antibodies in the veterinary setting.